Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study

Jordi Bruix; Won-Young Tak; Antonio Gasbarrini; Armando Santoro; Massimo Colombo; Ho-Yeong Lim; Vincenzo Mazzaferro; Reiner Wiest; María Reig; Andrea Wagner; Luigi Bolondi

doi:10.1016/j.ejca.2013.05.028

Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study

Jordi Bruix
, Won-Young Tak
, Antonio Gasbarrini
, Armando Santoro
, Massimo Colombo
, Ho-Yeong Lim
, Vincenzo Mazzaferro
, Reiner Wiest
, María Reig
, Andrea Wagner
, Luigi Bolondi

Risultato della ricerca: Contributo in rivista › Articolo

154 Citazioni (Scopus)

Abstract

We assessed the safety of the multikinase inhibitor regorafenib in patients with hepatocellular carcinoma (HCC) that had progressed following first-line sorafenib.

Lingua originale	Inglese
pagine (da-a)	3412-3419
Numero di pagine	8
Rivista	European Journal of Cancer
Volume	49
DOI	https://doi.org/10.1016/j.ejca.2013.05.028
Stato di pubblicazione	Pubblicato - 2013

Keywords

Adult
Aged
Antineoplastic Agents
Asia
Carcinoma, Hepatocellular
Disease Progression
Drug Administration Schedule
Europe
Female
Hepatocellular carcinoma
Humans
Kaplan-Meier Estimate
Liver Neoplasms
Male
Middle Aged
Neoplasm Staging
Phenylurea Compounds
Protein Kinase Inhibitors
Pyridines
Receptor kinase inhibition
Regorafenib
Safety
Second line
Time Factors
Tolerability
Treatment Outcome

Accesso al documento

10.1016/j.ejca.2013.05.028

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Bruix, J., Tak, W.-Y., Gasbarrini, A., Santoro, A., Colombo, M., Lim, H.-Y., Mazzaferro, V., Wiest, R., Reig, M., Wagner, A., & Bolondi, L. (2013). Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. European Journal of Cancer, 49, 3412-3419. https://doi.org/10.1016/j.ejca.2013.05.028

@article{d351b8f66f9046ee88381d2b9f909522,

title = "Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study",

abstract = "We assessed the safety of the multikinase inhibitor regorafenib in patients with hepatocellular carcinoma (HCC) that had progressed following first-line sorafenib.",

keywords = "Adult, Aged, Antineoplastic Agents, Asia, Carcinoma, Hepatocellular, Disease Progression, Drug Administration Schedule, Europe, Female, Hepatocellular carcinoma, Humans, Kaplan-Meier Estimate, Liver Neoplasms, Male, Middle Aged, Neoplasm Staging, Phenylurea Compounds, Protein Kinase Inhibitors, Pyridines, Receptor kinase inhibition, Regorafenib, Safety, Second line, Time Factors, Tolerability, Treatment Outcome, Adult, Aged, Antineoplastic Agents, Asia, Carcinoma, Hepatocellular, Disease Progression, Drug Administration Schedule, Europe, Female, Hepatocellular carcinoma, Humans, Kaplan-Meier Estimate, Liver Neoplasms, Male, Middle Aged, Neoplasm Staging, Phenylurea Compounds, Protein Kinase Inhibitors, Pyridines, Receptor kinase inhibition, Regorafenib, Safety, Second line, Time Factors, Tolerability, Treatment Outcome",

author = "Jordi Bruix and Won-Young Tak and Antonio Gasbarrini and Armando Santoro and Massimo Colombo and Ho-Yeong Lim and Vincenzo Mazzaferro and Reiner Wiest and Mar{\'i}a Reig and Andrea Wagner and Luigi Bolondi",

year = "2013",

doi = "10.1016/j.ejca.2013.05.028",

language = "English",

volume = "49",

pages = "3412--3419",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study

AU - Bruix, Jordi

AU - Tak, Won-Young

AU - Gasbarrini, Antonio

AU - Santoro, Armando

AU - Colombo, Massimo

AU - Lim, Ho-Yeong

AU - Mazzaferro, Vincenzo

AU - Wiest, Reiner

AU - Reig, María

AU - Wagner, Andrea

AU - Bolondi, Luigi

PY - 2013

Y1 - 2013

N2 - We assessed the safety of the multikinase inhibitor regorafenib in patients with hepatocellular carcinoma (HCC) that had progressed following first-line sorafenib.

AB - We assessed the safety of the multikinase inhibitor regorafenib in patients with hepatocellular carcinoma (HCC) that had progressed following first-line sorafenib.

KW - Adult

KW - Aged

KW - Antineoplastic Agents

KW - Asia

KW - Carcinoma, Hepatocellular

KW - Disease Progression

KW - Drug Administration Schedule

KW - Europe

KW - Female

KW - Hepatocellular carcinoma

KW - Humans

KW - Kaplan-Meier Estimate

KW - Liver Neoplasms

KW - Male

KW - Middle Aged

KW - Neoplasm Staging

KW - Phenylurea Compounds

KW - Protein Kinase Inhibitors

KW - Pyridines

KW - Receptor kinase inhibition

KW - Regorafenib

KW - Safety

KW - Second line

KW - Time Factors

KW - Tolerability

KW - Treatment Outcome

KW - Adult

KW - Aged

KW - Antineoplastic Agents

KW - Asia

KW - Carcinoma, Hepatocellular

KW - Disease Progression

KW - Drug Administration Schedule

KW - Europe

KW - Female

KW - Hepatocellular carcinoma

KW - Humans

KW - Kaplan-Meier Estimate

KW - Liver Neoplasms

KW - Male

KW - Middle Aged

KW - Neoplasm Staging

KW - Phenylurea Compounds

KW - Protein Kinase Inhibitors

KW - Pyridines

KW - Receptor kinase inhibition

KW - Regorafenib

KW - Safety

KW - Second line

KW - Time Factors

KW - Tolerability

KW - Treatment Outcome

UR - http://hdl.handle.net/10807/52151

U2 - 10.1016/j.ejca.2013.05.028

DO - 10.1016/j.ejca.2013.05.028

M3 - Article

SN - 0959-8049

VL - 49

SP - 3412

EP - 3419

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo